DarkPulse signs patent license deal with UMBRA Technologies

DarkPulse Inc. (OTCQB: DPLS) announced it has entered into a patent and trademark license agreement with UMBRA Technologies Ltd. and UMBRA Technologies (US) Inc.

The agreement grants DarkPulse a nonexclusive, royalty-bearing license to UMBRA's U.S. patent portfolio for critical infrastructure monitoring applications using DarkPulse's Brillouin Optical Time Domain Analysis distributed fiber-optic sensor deployments. The license also covers UMBRA's broader patent rights, know-how and trademarks within defined fields, limited to the United States.

UMBRA Technologies, founded in 2012 and based in Providence, Rhode Island, develops AI-enhanced secure network optimization and software-defined wide area networking solutions. Its Global Virtual Network platform uses the patented Slingshot multi-threaded routing system and UMBRA adaptive data-obfuscation engine.

Key licensed patents include U.S. Patent No. 10,630,505 for multi-perimeter firewall and cloud security, U.S. Patent No. 10,922,286 and related patents for network routing and remote direct memory access, and multiple recently issued patents covering AI-driven obfuscation and secure virtual networking.

DarkPulse develops fiber-optic sensors that provide strain and temperature measurements for structural health monitoring and perimeter security across energy, transportation and infrastructure markets. The company's sensors offer 20-millimeter spatial resolution for monitoring pipelines, railways, bridges, dams and other assets.

"UMBRA's Slingshot and GVN technologies represent the gold standard in secure, high-volume data transport," said Dennis O'Leary, chairman and chief executive officer of DarkPulse.

The licensing agreement creates opportunities for exclusivity arrangements through additional royalty payments linked to future deployment verticals, according to the press release.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Mesoblast reaches 300-patient enrollment in back pain Phase 3 trial
• NXG Cushing Midstream Energy Fund launches at-market share offering